COMMUNIQUÉS West-GlobeNewswire

KBP BioSciences Signs Memorandum of Understanding with BullFrog AI
07/08/2019
Envisions Using BullFrog AI Innovative Artificial Intelligence Technology to Expand KBP’s Diverse Product Pipeline PRINCETON, N.J. and JINAN, China, Aug. 07, 2019 (GLOBE NEWSWIRE) -- KBP BioSciences USA , a clinical [...]
Jounce Therapeutics Reports Second Quarter 2019 Financial Results
07/08/2019
- Initiated Phase 2 EMERGE trial of vopratelimab - - Completed enrollment of Phase 1 trial of JTX-4014 - - Updated strategic collaboration and established new licensing agreement with Celgene, received $50.0 million [...]
Cambrex to be Acquired by the Permira Funds for $60.00 per Share in Cash
07/08/2019
EAST RUTHERFORD, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug [...]
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2019
07/08/2019
CAMBRIDGE, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today [...]
La Fondation de l’Institut de Cardiologie de Montréal s’associe à Roller Marathon Canada dans le cadre du programme Cours pour le Cœur
07/08/2019
MONTRÉAL, 07 août 2019 (GLOBE NEWSWIRE) -- Vous aimeriez combiner envie de bouger et générosité? Cette année, la Fondation de l’Institut de Cardiologie de Montréal est heureuse de pouvoir compter sur le soutien de [...]
Athenex Announces Oral Paclitaxel and Encequidar had a Significantly Higher Response Rate Over IV Paclitaxel in a Phase III Pivotal Study in Metastatic Breast Cancer
07/08/2019
Study met primary endpoint showing statistically significant improvement in overall response rate for oral paclitaxel and encequidar (Oral Paclitaxel) compared to IV paclitaxel based on intention-to-treat (ITT) analysis [...]
RavenQuest Provides Shareholder Update
07/08/2019
VANCOUVER, British Columbia, Aug. 07, 2019 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) , one of Canada’s most innovative cannabis companies, [...]
Athenex, Inc. Announces Second Quarter 2019 Financial Results, Positive Phase III Results on Oral Paclitaxel plus Encequidar and Increased Product Sales Guidance
07/08/2019
Positive Phase III results of Oral Paclitaxel show statistically significant improvement in overall response rate in metastatic breast cancer Company is preparing two NDA submissions following successful Phase III [...]
EyePoint Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress
07/08/2019
– Company reports total revenue of $7.2 million – – Two commercial product launches in U.S. are underway for DEXYCU ® and YUTIQ ® with 43 sales reps actively targeting uveitis specialists, cataract surgeons and [...]
Sales of darolutamide started in the USA – Orion receives EUR 45 million milestone
07/08/2019
ORION CORPORATION PRESS RELEASE 7 AUGUST 2019 at 10.30 am EEST Sales of darolutamide started in the USA – Orion receives EUR 45 million milestone Sales of Nubeqa® (darolutamide), jointly developed by Orion Corporation [...]
ObsEva SA Announces $75 Million Credit Facility with Oxford Finance LLC
07/08/2019
Geneva, Switzerland and Boston, MA – August 7, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for [...]
ObsEva Reports Second Quarter 2019 Financial Results
07/08/2019
Multiple Major Milestones Expected This Year - Q4:19 Phase 3 data for IMPLANT 4 trial of nolasiban - Nolasiban MAA submission targeted for year- end 2019 - Q4:19 Phase 3 data for PRIMROSE 2 trial of linzagolix in [...]
Allakos Announces Upsizing and Pricing of Public Offering of Common Stock
07/08/2019
REDWOOD CITY, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today [...]
Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 in Wet AMD
07/08/2019
OPT-302 Combination Therapy Demonstrated Superiority in Visual Acuity over Lucentis ® Company to Host Conference Call Today at 9:00 AM AEST 7:00PM EDT (Tuesday, August 6th U.S) -Dial-in details posted at end of release [...]
Novartis stands behind Zolgensma® (onasemnogene abeparvovec-xioi) for the treatment of children less than 2 years of age with spinal muscular atrophy
07/08/2019
Basel, August 6, 2019 – Today the FDA released a statement addressing data integrity issues with the Biologics License Application (BLA) for Zolgensma® (onasemnogene abeparvovec-xioi). First and foremost, we are fully [...]
Melinta Therapeutics Announces Rescheduling of Second Quarter 2019 Financial Results Reporting
06/08/2019
~ Second Quarter 2019 Financial Results to be Reported on Friday, August 9, 2019 ~ ~ Company Cancels Previously Scheduled Earnings Call ~ MORRISTOWN, N.J., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. ( [...]
National Research Corporation Announces Second Quarter 2019 Results
06/08/2019
LINCOLN, Neb., Aug. 06, 2019 (GLOBE NEWSWIRE) -- National Research Corporation (NASDAQ:NRC) today announced results for the second quarter of 2019. Net New Sales of $6.1 million up 14% Revenue increased 12% to $31.4 [...]
Supernus Announces Second Quarter 2019 Financial Results
06/08/2019
Total revenue of $104.7 million, a 5.2% increase over 2018 Net product sales of $102.4 million, a 5.5% increase over 2018 Operating earnings of $42.6 million, a 19.3% increase over 2018 Submission of New Drug [...]
Clearside Biomedical to Present at the 2019 Wedbush PacGrow Healthcare Conference
06/08/2019
ALPHARETTA, Ga., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye [...]

Pages